![]() |
市场调查报告书
商品编码
1401078
鞘内泵全球市场规模、占有率和行业趋势分析报告:2023-2030 年按应用、类型和地区分類的展望和预测Global Intrathecal Pumps Market Size, Share & Industry Trends Analysis Report By Application (Pain, and Spasticity), By Type (Morphine, Ziconotide, Baclofen, Bupivacaine, Clonidine, and Others), By Regional Outlook and Forecast, 2023 - 2030 |
到 2030 年,鞘内帮浦市场规模预计将达到 4.917 亿美元,预测期内复合年增长率为 5.7%。
此外,COVID-19 大流行对市场产生了中等影响。在大流行的早期阶段,许多选择性手术和医疗程序被推迟或取消,包括与鞘内泵植入相关的手术和医疗程序。医院和医疗机构面临优先处理 COVID-19 病例的巨大压力,导致非紧急手术的延迟。这种延迟影响了市场的成长轨迹。这是因为病人延后了择期手术,影响了新入院和替代手术。疫情导致的全球供应链中断影响了医疗设备和零件的可得性。这些泵浦和相关配件的製造商面临原材料采购、生产延误和物流问题的挑战。这些干扰导致市场波动,影响供需双方。因此,由于这些变化,预计市场在未来几年将显着成长。
然而,由于庞大的初期成本,包括帮浦、手术植入和相关程序的成本,鞘内帮浦治疗可能会造成财务障碍。保险不足或经济能力有限的患者在获得这种先进治疗方法可能面临挑战。不一致或不充分的报销政策可能会阻碍鞘内泵治疗的广泛普及。缺乏保险报销或保险报销率不足以支付与治疗相关的费用可能会阻碍医疗保健提供者提供这种治疗作为治疗选择。患者的经济负担可能导致患者医嘱遵从性性下降、不愿意接受鞘内泵治疗或可能停止治疗。由于上述方面,预计未来几年市场成长将下降。
按用途分類的展望
根据应用,市场分为痉挛和疼痛。 2022 年,痉挛细分市场在市场中占据了重要的收益占有率。巴氯芬等药物直接给药脊髓。巴氯芬是一种肌肉鬆弛剂,作用于中枢神经系统以减轻痉挛。标靶化使药物在作用部位的浓度更合适,从而更好地控制肌张力和痉挛。透过鞘内帮浦治疗控制痉挛可以改善肌肉功能和活动范围。这使得物理治疗和復健更加有效,并提高整体运动能力和功能。
按类型分類的展望
依类型划分,市场分为巴氯芬、布比卡因、可乐定、吗啡、齐考诺肽等。 2022年,吗啡细分市场以最大的收益占有率主导市场。吗啡因其强大的受体亲和性、稳定的性能和广泛的用户知识而成为鞘内给药的基准。此外,吗啡已获得美国FDA 核准作为长期鞘内疼痛治疗药物。此外,与全身性鸦片类药物相比,长期鞘内注射吗啡副作用较少,预计将刺激该细分市场的成长。据世界卫生组织称,吗啡等鸦片类药物经常被处方,因为它们能够缓解不适。阿片类药物可有效缓解从急性到慢性的各种疼痛。鸦片类药物透过作用于大脑和脊髓中的特定受体来减少疼痛讯号。
区域展望
从区域来看,我们对北美、欧洲、亚太地区和拉丁美洲地区的市场进行了分析。 2022年,北美地区的收益占有率最高。设备齐全的初级、二级和三级医疗机构的存在促进了北美市场的成长。此外,有利的政府津贴和强大的报销网络预计将推动市场扩张。主要市场参与企业不断加强合作,以增强其产品线并确保卓越的质量,预计将刺激该地区对鞘内泵的需求。美国癌症发生率不断上升,推动了对先进有效鞘内泵的需求不断增长。
The Global Intrathecal Pumps Market size is expected to reach $491.7 million by 2030, rising at a market growth of 5.7% CAGR during the forecast period.
Bupivacaine is regarded as an exceptional adjunctive drug in intrathecal therapy. Thus, the Bupivacaine segment acquired $36,149.5 thousand in 2022. The synergistic enhancement of intrathecal opioid effects when bupivacaine is combined with them has been demonstrated in multiple studies, which has contributed significantly to its expanding market share. Bupivacaine reduces dose escalations of intrathecal opioids and permits some patients to reduce their oral opioid utilization. Thus, it is envisaged that several benefits associated with bupivacaine will sustain segment expansion. Some of the factors impacting the market are technological advancements in pump design, expanding applications in pain management and neurological disorders, and high initial costs and economic considerations.
Modern intrathecal pumps have advanced mechanisms that enable precise and accurate drug delivery. This precision is crucial for administering the proper medication dosage directly to the spinal cord, optimizing therapeutic effects while minimizing the risk of side effects. The integration of smart pump technologies has enhanced the capabilities of intrathecal pumps. These technologies often include remote monitoring, connectivity, and data analytics features. Healthcare providers can remotely monitor patient data, receive real-time alerts, and adjust the pump settings, improving overall patient care and management. Additionally, intrathecal pumps were initially developed for pain management, but their successful application has expanded to address a variety of neurological disorders, including spasticity, dystonia, and severe cases of Parkinson's disease. This diversification broadens the potential patient population benefitting from intrathecal pump therapy. Using these pumps in neurological disorders improves functionality and mobility in affected individuals. By directly targeting the underlying neurological mechanisms, these pumps help reduce muscle spasticity, dystonia, and other symptoms that can enormously impact a person's ability to move and perform daily activities. Healthcare teams comprising pain specialists, neurologists, and other relevant specialists collaborate to develop comprehensive treatment plans that address pain and associated neurological symptoms. Thus, the above-mentioned factors will expand the market growth.
Further, the COVID-19 pandemic moderately impacted the market. Many elective surgeries and medical procedures, including those related to intrathecal pump implantation, were postponed, or canceled during the initial phases of the pandemic. Hospitals and healthcare facilities were under immense pressure to prioritize COVID-19 cases, leading to delays in non-urgent procedures. This delay had influenced the market's growth trajectory, as patients defer elective surgeries, affecting both new installations and replacements. The global disruptions in supply chains caused by the pandemic have affected the availability of medical devices and components. Manufacturers of these pumps and related accessories faced challenges in procuring raw materials, production delays, and logistical issues. These disruptions contributed to fluctuations in the market, affecting both the supply and demand sides. As a result, due to these changes, the market is expected to grow significantly in the coming years.
However, the substantial upfront costs associated with intrathecal pump therapy, including the cost of the pump, surgical implantation, and related procedures, can create financial barriers to access. Patients without adequate insurance coverage or financial resources may face challenges accessing this advanced treatment option. Inconsistent or inadequate reimbursement policies can hinder the widespread adoption of intrathecal pump therapy. The lack of reimbursement or reimbursement rates that do not adequately cover the costs associated with the therapy may discourage healthcare providers from offering it as a treatment option. The financial burden on patients could lead to decreased patient adherence, reluctance to pursue intrathecal pump therapy or potential treatment discontinuation. Due to the above aspects, market growth is expected to decline in the coming years.
Application Outlook
Based on application, the market is fragmented into spasticity and pain. The spasticity segment garnered a significant revenue share in the market in 2022. It delivers medications, such as baclofen, directly to the spinal cord. Baclofen is a muscle relaxant that operates on the central nervous system to reduce spasticity. The targeted delivery allows for a more adequate concentration of the drug at its site of action, leading to better control of muscle tone and spasticity. Controlling spasticity through intrathecal pump therapy can improve muscle function and range of motion. This allows individuals to engage in physical therapy and rehabilitation more effectively, improving overall mobility and functionality.
Type Outlook
On the basis of type, the market is segmented into baclofen, bupivacaine, clonidine, morphine, ziconotide, and others. In 2022, the morphine segment dominated the market with the maximum revenue share. Morphine is the benchmark for intrathecal drug delivery due to its robust affinity for receptors, consistent performance, and substantial body of user knowledge. Furthermore, morphine has been granted sanction by the US FDA for the treatment of long-term intrathecal pain. Furthermore, compared to systemic opioids, long-term intrathecal morphine has fewer adverse effects, which is anticipated to stimulate the growth of this market segment. Owing to their ability to alleviate discomfort, opioids like morphine are frequently prescribed, per the WHO. They efficiently alleviate a wide range of pain, encompassing both acute and chronic ailments. Pain signals are diminished through the action of these medications on specific receptors in the brain and spinal cord.
Regional Outlook
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the North America region registered the highest revenue share in the market. The presence of adequately equipped primary, secondary, and tertiary care facilities bolstered growth in the North American market. In addition, favorable government funding and a robust reimbursement network are anticipated to drive market expansion. Expected to stimulate demand for intrathecal pumps in this region are the increasing collaborative efforts of key market participants to enhance their product lines and guarantee superior quality. An increased demand for sophisticated and effective intrathecal pumps is a result of the escalating incidence of cancer in the United States.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic plc, ICU Medical, Inc. (Smiths Medical), Teleflex, Inc., Johnson & Johnson (Johnson & Johnson Services, Inc.), Baxter International, Inc., Abbott Laboratories, Tricumed Medizintechnik GmbH, Flowonix Medical, Inc., Durect Corporation, and Novartis AG
Market Segments covered in the Report:
By Application
By Type
By Geography
Companies Profiled
Unique Offerings from KBV Research